April 2013 Vol 4, No 2
On behalf of myself and the wonderful AONN staff and Leadership Council that I have the privilege of working with, we hope that you are enjoying the new features and benefits we have been launching for you through the AONN website.
Most navigators are familiar with the large national patient advocacy organizations that provide various resources for patients that can expedite our ability to reduce barriers impeding diagnosis and treatment, but there are actually additional resources that you may not be aware of that I want to tell you about. These resources are from pharmaceutical companies and other device and laboratory testing companies.
In March, the National Comprehensive Cancer Network (NCCN) guidelines for genetic/familial high-risk assessment for breast and ovarian cancers were updated. Among the updates is a section on “gene panels.”
Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG, Julie K. Silver, MD, Elissa Bantug, MHS, Laurie Sweet, PT, R. Samuel Mayer, MD, Michael Friedman, PT, MBA
More than 40% of individuals born today will develop some type of cancer during their lifetime.
Since the publication of the positive results of the National Lung Screening Trial (NLST)—the first lung cancer screening trial to demonstrate a reduction in lung cancer mortality—in the New England Journal of Medicine in 2011, several uncertainties regarding implementation of widespread lung cancer screening have arisen.
Although planning for survivorship care is recognized as an important part of the continuum of cancer care, end-of-treatment summaries (TSs) and survivorship care plans (SCPs) are not universally provided to cancer patients, even at centers of excellence. That situation is about to change over the next few years, however, because the Commission on Cancer (CoC) says that these plans will be mandatory by 2015.
Real-life experience translated into a research interest for Fedricker Barber, RN, ANP, AOCNP, of the MD Anderson Cancer Center in Houston, Texas.
Results 1 - 7 of 7
